AbCellera
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
| Company type | Public |
|---|---|
Traded as | Nasdaq: ABCL |
| Industry | Biotechnology |
| Founded | 2012 |
| Headquarters | Vancouver, British Columbia |
| Revenue | 375.2 million (2021) |
Number of employees | 386 (2021) |
| Website | www |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.